Resources

Up to now, the benefits and growth potential of cell and gene therapies for cancer treatment have been restricted by variabilities in development and clinical results. This variability stems from three main factors: tumor/host biology, inherent tumor resistance mechanisms, and variability in the cell therapy product itself. Excellos™360 employs Excellos’s deep cell characterization approach to address these variabilities by going deeper than typical cell and donor screening to create a comprehensive immune cell profile for each donor, as well as an assessment of the metabolic and effector potential of their cells that sees beyond surface markers. Using this approach, Excellos 360 is working to improve the potency of cell-based treatments for reduced clinical response variability, in order to:

• Improve clinical outcomes
• Lower safety liability by making therapies effective in lower dosages
• Lower the cost of goods associated with cell and gene therapy manufacture.

Excellos 360 will allow you to accelerate the development and production of more effective and accessible cell and immunotherapy treatments.

Excellos 360 employs Excellos’s deep cell characterization approach to address these by going deeper than typical cell and donor screening to create a comprehensive immune cell profile for each donor, as well as an assessment of the metabolic and effector potential of their cells that looks beyond surface markers

Watch the Video on The Excellos Difference: